Fig. 1
From: A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy
Antigen designs of KRASG12D as encoded by non-integrative lentiviral vectors. A Scheme of KRAS1-23G12D protein segment: alone (top), fused at its N-terminal extremity with full length li to facilitate its routing through the MHC-II pathway (middle), or fused at its N-terminal extremity with li-DT (bottom). B Protein sequences of the KRASG12D (25 aa), li-KRASG12D (244 aa) and li-DT-KRASG12D (425 aa) antigens. The lower-case characters indicate linkers inserted between the sequences to avoid generation of irrelevant junctional T cell epitopes. KRAS1-23G12D substitution is indicated in red bold. The KRASG12D sequence is in black, li sequence in grey and DT sequence in blue.
